Cargando…

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?

SIMPLE SUMMARY: In patients with progressive metastatic radioiodine-refractory differentiated thyroid cancer, tyrosine kinase inhibitor (TKI) therapy with lenvatinib improves progression-free survival. Early identification of patients with therapeutic responses to the TKI therapy is clinically relev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rendl, Gundula, Schweighofer-Zwink, Gregor, Sorko, Stefan, Gallowitsch, Hans-Jürgen, Hitzl, Wolfgang, Reisinger, Diana, Pirich, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029268/ https://www.ncbi.nlm.nih.gov/pubmed/35454777 http://dx.doi.org/10.3390/cancers14081868

Ejemplares similares

Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
por: Ziai, D., et al.
Publicado: (2013)

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST
por: Depardon, Edouard, et al.
Publicado: (2018)

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
por: Rendl, G., et al.
Publicado: (2020)

EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
por: Lasnon, Charline, et al.
Publicado: (2017)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria
por: Devriese, Joke, et al.
Publicado: (2018)

Feasibility of equivalent performance of 3D TOF [(18)F]-FDG PET/CT with reduced acquisition time using clinical and semiquantitative parameters
por: Pilz, Julia, et al.
Publicado: (2021)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
por: Vogsen, Marianne, et al.
Publicado: (2021)

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

Predictive value and accuracy of [(18)F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
por: Ayati, Narjess, et al.
Publicado: (2023)

A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article
por: Nakajo, Masatoyo, et al.
Publicado: (2021)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

Evolving Role of [(18)F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach?
por: Seyedinia, Seyedeh Sara, et al.
Publicado: (2023)

Factors That Affect PERCIST-Defined Test-Retest Comparability: An Exploration of Feasibility in Routine Clinical Practice
por: Yuan, Hui, et al.
Publicado: (2015)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg
por: Rendl, Gundula, et al.
Publicado: (2017)

Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020)

Quantitation of cancer treatment response by 2-[(18)F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
por: O, Joo Hyun, et al.
Publicado: (2021)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite—Where Does the Balance Exist?
por: Bhoil, Amit
Publicado: (2023)

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Response criteria in solid tumors (PERCIST/RECIST) and SUV(max) in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
por: Pierson, Cory, et al.
Publicado: (2018)

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
por: Gupta, Manoj, et al.
Publicado: (2022)

Head-to-Head Comparison of CZT-SPECT and SPECT/CT Myocardial Perfusion Imaging: Interobserver and Intraobserver Agreement and Diagnostic Performance
por: Kalantari, Forough, et al.
Publicado: (2023)

A method for evaluation of patient-specific lean body mass from limited-coverage CT images and its application in PERCIST: comparison with predictive equation
por: Shang, Jingjie, et al.
Publicado: (2021)

Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy
por: Fledelius, Joan, et al.
Publicado: (2016)

Incremental Impact of [(68) Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI
por: Szigeti, Florian, et al.
Publicado: (2021)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status
por: Steiner, Florian, et al.
Publicado: (2016)

Impact of [(18)F]FDG PET/CT in the Assessment of Immunotherapy-Induced Arterial Wall Inflammation in Melanoma Patients Receiving Immune Checkpoint Inhibitors
por: Ranjbar, Shaghayegh, et al.
Publicado: (2023)

Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods
por: Schaffler-Schaden, Dagmar, et al.
Publicado: (2020)

Which Are the Most Suitable Stents for Interventional Endoscopic Ultrasound?
por: Park, Se Woo, et al.
Publicado: (2020)

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends
por: Manafi-Farid, Reyhaneh, et al.
Publicado: (2021)

(18)F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with (99m)Tc-MIBI or (99m)Tc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients
por: Beheshti, Mohsen, et al.
Publicado: (2018)

Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/ MSG and ICU criteria
por: Huang, Linna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3pjv8jbtjqmk4qsbofnp01b1gj